Kami Maddocks, MD
Enriched profileProfessor of Clinical Internal Medicine, Division of Hematology · The Ohio State University Wexner Medical Center
Kami Maddocks is Professor of Clinical Internal Medicine, Division of Hematology at The Ohio State University Wexner Medical Center. OpenAlex indexes 400 publications with 10,287 citations (h-index 46); ClinicalTrials.gov lists 7 registered studies with this person as an investigator.
Data verified 12 Oct 2026
Overview
Updated 14 Oct 2026
Kami Maddocks, MD, is Professor of Clinical Internal Medicine, Division of Hematology at The Ohio State University Wexner Medical Center / OSUCCC - James. The public record shows 400 publications with 10,287 citations (h-index 46), centered on Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, Viral-associated cancers and disorders. It also documents an investigator role on 7 registered clinical trials, industry payments reported by 22 companies, 1 NIH-funded awards (2026–2026).
- Most recent indexed publication: 2026 · medRxiv
- Top research focus: Lymphoma Diagnosis and Treatment
- 7 registered trials on ClinicalTrials.gov
- Open Payments reporting from 22 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 6 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 139.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 7 registered studies on ClinicalTrials.gov. The most recent:
- Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
Sponsor: National Cancer Institute (NCI)
- Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma
Sponsor: Ohio State University Comprehensive Cancer Center
- Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma
Sponsor: Alliance Foundation Trials, LLC.
Industry payments
Updated 14 Oct 2026
22 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- ADC THERAPEUTICS AMERICA, INC.Program year20258 payments$13,197openpaymentsdata.cms.gov ↗
- Incyte CorporationProgram year202512 payments$10,970openpaymentsdata.cms.gov ↗
- ABBVIE INC.Program year202514 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Kinase inhibitor89.6%Brukinsa48%Calquence38%Imbruvica14%Part D<11 patientsBCL-2 Inhibitor10.4%Venclexta100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 14 Oct 2026
1 NIH research award on record, funded 2026–2026 per NIH RePORTER. The latest:
Congress activity
Updated 14 Oct 2026
111 congress contributions (2012–2026) across AACR, ASCO, ASH per OpenAlex. The most recent:
- Abstract 912: Non-Hodgkin’s lymphoma survival by neighborhood disinvestment and socioeconomic composition.
AACR Annual Meeting
AACR2026Co-author - Anti-CD19 chimeric antigen receptor T-cell therapy for patients with non-Hodgkin's lymphoma and concurrent autoimmune disease
ASH Annual Meeting
ASH2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Clinical characteristics associated with terminal methotrexate clearance in patients with non-Hodgkin lymphomas receiving high-dose methotrexate.
Journal of oncology pharmacy practice
Article2026 - Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study.
Blood advances
Clinical Trial2025
Most-cited works
by citation count (OpenAlex)- 01
- 02
- 03
- 04BTK C481S -Mediated Resistance to Ibrutinib in Chronic Lymphocytic LeukemiaArticle482 citations2017
- 05Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemiaArticle473 citations2016
Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
University of South Dakota Sanford School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bloodcancerstoday.com ↗
Editorial & leadership roles
journal and society appointments- Associate Editor
Blood Cancers Today
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bloodcancerstoday.com ↗ - Member
Alliance Lymphoma Committee
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cancer.osu.edu ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ajmc.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Timothy Pawlik, MD
The Ohio State University Wexner Medical Center
Raphael Pollock, MD, PhD
The Ohio State University Wexner Medical Center
John Kissel, MD
The Ohio State University Wexner Medical Center
Douglas Scharre, MD
The Ohio State University Wexner Medical Center
Seth Steinberg, PhD
National Cancer Institute (NCI)
Gilles Salles
Memorial Sloan Kettering Cancer Center
Wyndham Wilson, MD
National Cancer Institute (NCI)
Julie Vose, MD
University of Nebraska Medical Center